ETHRIS
ETHRIS develops mRNA therapeutics with a focus on respiratory diseases and vaccines. ETHRIS possesses an enabling LNP delivery and mRNA modification platform for transcript Therapies. SNIM®RNAis a first-in-class biopharmaceutical which provide a compelling alternative for recombinant protein or gene therapies. SNIM®RNAs encode therapeutic proteins to be produced in the patient‘s body and overcome short duration effects of recombinant proteins. SNIM®RNA Transcript Therapy is a new option for a broad variety of diseases, either acquired or genetically predetermined, lifestyle- or age-related, rare or frequent.
ETHRIS
Industry:
Bioinformatics Biopharma Biotechnology Genetics Pharmaceutical
Founded:
2009-01-01
Address:
Planegg, Bayern, Germany
Country:
Germany
Website Url:
http://www.ethris.com
Total Employee:
101+
Status:
Active
Contact:
+4908989557880
Email Addresses:
[email protected]
Total Funding:
74.42 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Nginx Euro Microsoft Exchange Online Office 365 Mail IPv6
Similar Organizations
Bicycle Therapeutics
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Current Employees Featured
Founder
Investors List
Laureus Capital
Laureus Capital investment in Series B - ETHRIS
Bavarian Ministry of Economics / Bayerisches Wirtschaftsministerium
Bavarian Ministry of Economics / Bayerisches Wirtschaftsministerium investment in Grant - ETHRIS
AstraZeneca
AstraZeneca investment in Corporate Round - ETHRIS
OrbiMed
OrbiMed investment in Series A - ETHRIS
HS LifeSciences
HS LifeSciences investment in Series A - ETHRIS
Official Site Inspections
http://www.ethris.com Semrush global rank: 7.11 M Semrush visits lastest month: 588
- Host name: vwp4608.webpack.hosteurope.de
- IP address: 83.169.26.88
- Location: Germany
- Latitude: 51.4476
- Longitude: 7.0122
- Timezone: Europe/Berlin
More informations about "ETHRIS"
About - ETHRIS
About Ethris. Based in Planegg just outside Munich, Germany, Ethris was founded by Dr. Carsten Rudolph and Prof. Christian Plank to establish messenger RNA (mRNA) as a new drug …See details»
ETHRIS - Crunchbase Company Profile & Funding
ETHRIS develops mRNA therapeutics with a focus on respiratory diseases and vaccines. ETHRIS possesses an enabling LNP delivery and mRNA modification platform for transcript Therapies. …See details»
Ethris joins Alliance for mRNA Medicines - News | ETHRIS
Munich, Germany, November 1, 2023 - Ethris GmbH, a leading biotechnology company pioneering next-generation messenger RNA (mRNA) therapeutics and vaccines, announced …See details»
Ethris Joins Alliance for mRNA Medicines as a Founding
Nov 1, 2023 Ethris has paved a new path from genes to therapeutic proteins, using its proprietary RNA and lipidoid nanoparticle technology platform to discover, design and develop …See details»
Ethris Company Profile 2024: Valuation, Funding & Investors
Ethris General Information Description. Developer of stabilized non-immunogenic mRNA platform designed to develop innovative therapies and vaccines. The company's platform uses a …See details»
Company Information - RocketReach
The NAICS codes for Ethris are [54171, 541, 541714, 54, 5417]. What is the SIC code for Ethris? The SIC codes for Ethris are [87, 873]. Top Ethris Employees Nigel Horscroft Senior Vice …See details»
ETHRIS - Funding, Financials, Valuation & Investors - Crunchbase
ETHRIS is a technical innovator in the emerging field of mRNA therapeutics and LNP delivery. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. ... How much …See details»
Ethris - Company Profile - Tracxn
Oct 22, 2024 Ethris ranks 249th among 2728 active competitors. 734 of its competitors are funded while 492 have exited. Overall, Ethris and its competitors have raised over $39.3B in …See details»
ethris - The Org
Ethris is a technical innovator in the emerging field of messenger RNA therapeutics. Industries. BiotechnologySee details»
Ethris - Products, Competitors, Financials, Employees, …
Ethris. Frequently Asked Questions (FAQ) When was Ethris founded? Ethris was founded in 2009. Where is Ethris's headquarters? Ethris's headquarters is located at Semmelweisstr. 3, …See details»
Ethris Company Profile - Office Locations, Competitors, Revenue
Ethris is a biopharmaceutical company focused on developing therapies for pulmonary diseases such as primary ciliary dyskinesia. It provides the Stabilized Non-Immunogenic mRNA (SNIM …See details»
Ethris - Overview, News & Similar companies | ZoomInfo.com
Dec 28, 2022 Ethris Raises $26.3 Million Series B to Advance Pipeline of mRNA-based Therapeutics for Respiratory Diseases MUNICH, Germany--(BUSINESS WIRE)--Ethris …See details»
Ethris - VentureRadar
Ethris is a technical innovator in the emerging field of messenger RNA therapeutics. We are using our proprietary technologies to develop a new approach for the treatment of pulmonary …See details»
ETHRIS GmbH - Drug pipelines, Patents, Clinical trials - Synapse
Nov 1, 2024 Explore ETHRIS GmbH with its drug pipeline, therapeutic area, technology platform, 16 news, and 35 literature, Disease Domain:Infectious Diseases, Immune System …See details»
Ethris – germantech.org – Network
Ethris is interested in collaborations for licensing of its technology platform, co-development of new mRNA vaccines and therapeutics, and licensing partners for future commercialization of …See details»
Ethris Company Information - Funding, Investors, and More
The company Ethris has raised a total of $31.4m in funding over 2 rounds. Key Insights: Series B: $26.4m; Series A: $5m; 2022. Ethris Series B (2022, $26M) $26.4m. 2024. Ethris Series A …See details»
Partnering - ETHRIS
Ethris’ goal is to become the leader in inhaled mRNA therapeutics and next-generation mRNA vaccines. Partnering Strategy Ethris is actively seeking to forge strategic partnerships and …See details»
ETHRIS COMPANY PRESENTATION - Swiss Biotech Day
Ethris manufacturing process offers multiple advantages compared to industry standard TFF Solvent free Modular setup Closed system Dephos-phorylation Industry standard Downstream …See details»
News - ETHRIS
Munich, Germany, June 18, 2024 – Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, announced today that it has received funding …See details»